Selected Quarterly Financial Data Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended												12 Months Ended
	Dec. 31, 2014		Sep. 30, 2014	Jun. 30, 2014		Mar. 31, 2014	Dec. 31, 2013		Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013		Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2013
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 190,998,000	[1],[2]	$ 172,401,000	$ 183,774,000	[1]	$ 177,235,000	$ 185,003,000	[3]	$ 174,282,000	$ 172,826,000	$ 155,753,000	[4]	$ 724,408,000	$ 687,864,000	$ 558,588,000
Cost of revenue	66,000,000	[1],[2]	69,076,000	85,687,000	[1]	66,867,000	76,339,000	[3]	65,794,000	63,938,000	56,714,000	[4]	287,630,000	262,785,000	177,339,000
Total operating expenses	225,779,000	[1],[2]	185,052,000	215,660,000	[1]	162,484,000	200,865,000	[3]	151,509,000	143,907,000	178,392,000	[4]	788,975,000	674,673,000	475,515,000
Net (loss) income	(5,323,000)	[1],[2]	(16,736,000)	(5,157,000)	[1]	(4,996,000)	1,198,000	[3]	7,793,000	18,094,000	(11,573,000)	[4]	(32,348,000)	15,260,000	51,170,000
Basic (USD per share)	$ (0.08)	[1],[2]	$ (0.26)	$ (0.08)	[1]	$ (0.08)	$ 0.02	[3]	$ 0.13	$ 0.33	$ (0.21)	[4]	$ (0.50)	$ 0.27	$ 0.96
Diluted (USD per share)	$ (0.08)	[1],[2]	$ (0.26)	$ (0.08)	[1]	$ (0.08)	$ 0.02	[3]	$ 0.12	$ 0.30	$ (0.21)	[4]	$ (0.50)	$ 0.25	$ 0.93
Business Acquisition [Line Items]
Settlement													25,736,000	0	0
Impairment charges	6,400,000			15,100,000
Incline Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Increase in contingent consideration							10,900,000
Decrease in deferred lax liability							13,600,000
Settlement	25,700,000
Alnylam Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Initial payment											$ 25,000,000					$ 25,000,000

[1] Net loss for the second and fourth quarters of 2014 includes impairment charges on product licenses in the amount of $15.1 million and $6.4 million, respectively to cost of sales, as a result of reductions in estimated future cash flows expected to be generated by the acute care generic products as determined by an updated discounted cash flow analysis (Level 3).

[2] In December 2014, the Company entered into a settlement and amendment to the merger agreement with Incline Therapeutics, Inc., which resulted in revisions to certain milestone triggers, a reduction in total milestone payments and the release of the escrow funds to the Company. As a result, net loss for the fourth quarter of 2014 includes $25.7 million in one-time income in connection with the settlement with the former equityholders of Incline related to the representations and warranties included in the merger agreement.

[3] Net income for the fourth quarter of 2013 includes a $10.9 million increase related to the progression in development work for IONSYS related to the Company’s Incline acquisition and a tax benefit of $13.6 million from reducing the Company’s deferred tax liabilities associated with the Incline acquisition.

[4] Net loss for the first quarter of 2013 includes licensing costs of $25.0 million for a transaction with Alnylam on the PCSK9 RNAi hypercholesterolemia program.